News

Under the agreed terms Intercell is expected to pay EUR15m to Cytos. Intercell is expected to own certain unpartnered monoclonal antibody assets, including promising pre-clinical anti-infective antibody candidates

PF-04523655 is a chemically-modified siRNA drug candidate being co-developed by Quark and Pfizer for the treatment of wet age-related macular degeneration (wet-AMD) and diabetic macular edema (DME). According

TB-402 is a new, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic surgery. The Phase II

URL Pharma said that these new dosing recommendations were issued as a result of several clinical studies designed and conducted by URL Pharma that uncovered the risk of

Tris Pharma has a first to file ANDA application for the generic that can entitle it to 180 days of generic exclusivity upon approval. Tris Pharma and Reckitt

The addition of ABS scientists and resources establishes UBC with the presence and operational reach in the New England biomedical corridor and adds to its portfolio of scientific

Amira Pharmaceuticals said that the LPA1 receptor is part of the phosphatidic acid/ lysophosphatidylcholine pathway and has recently been implicated for having a role in lung, kidney and

In the case, Merck had presented evidence that it acted appropriately in researching and developing Fosamax and in monitoring the medicine after it was placed on the market.

The published study results show that one year after a stenting procedure, patients treated with Abott’s Xience V Everolimus Eluting Coronary Stent System were less likely to have